UGT2B17

Summary

UGT2B17 (UDP glucuronosyltransferase family 2 member B17, HGNC:12547) is a protein-coding gene on chromosome 4q13.2, encoding UDP-glucuronosyltransferase 2B17 (O75795). UDP-glucuronosyltransferase (UGT) that catalyzes phase II biotransformation reactions in which lipophilic substrates are conjugated with glucuronic acid to increase the metabolite’s water solubility, thereby facilitating excretion into either the urine or bile.

This gene encodes a member of the uridine diphosphoglucuronosyltransferase protein family. The encoded enzyme catalyzes the transfer of glucuronic acid from uridine diphosphoglucuronic acid to a diverse array of substrates including steroid hormones and lipid-soluble drugs. This process, known as glucuronidation, is an intermediate step in the metabolism of steroids. Copy number variation in this gene is associated with susceptibility to osteoporosis.

Source: NCBI Gene 7367 — RefSeq curated summary.

At a glance

• GWAS associations: 9
• Clinical variants (ClinVar): 96 total
• Druggable target: yes
• MANE Select transcript: NM_001077

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:12547
Approved symbol	UGT2B17
Name	UDP glucuronosyltransferase family 2 member B17
Location	4q13.2
Locus type	gene with protein product
Status	Approved
Ensembl gene	ENSG00000197888
Ensembl biotype	protein_coding
OMIM	601903
Entrez	7367

Gene structure

Transcript identifiers

Ensembl transcripts: 4 — 4 protein_coding

ENST00000317746, ENST00000684088, ENST00000893234, ENST00000950879

RefSeq mRNA: 1 — MANE Select: NM_001077 NM_001077

CCDS: CCDS3523

Canonical transcript exons

ENST00000317746 — 7 exons

Exon	Start	End
ENSE00001364957	68537173	68537904
ENSE00001420935	68567761	68568548
ENSE00001597835	68550677	68550896
ENSE00001618641	68551824	68551911
ENSE00001670896	68565572	68565720
ENSE00001711753	68560537	68560668
ENSE00003916064	68575951	68576322

Expression profiles

Bgee: expression breadth ubiquitous, 128 present calls, max score 99.03.

FANTOM5 (CAGE): breadth tissue_specific, TPM avg 0.0152 / max 5.9502, expressed in 11 samples.

FANTOM5 promoters (2 alternative TSS)

Promoter ID	TPM avg	Samples expressed
52338	0.0077	8
203186	0.0075	3

Top tissues by expression

277 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
mucosa of transverse colon	UBERON:0004991	99.03	gold quality
ileal mucosa	UBERON:0000331	98.92	gold quality
mucosa of sigmoid colon	UBERON:0004993	95.33	gold quality
duodenum	UBERON:0002114	92.02	gold quality
vermiform appendix	UBERON:0001154	91.35	gold quality
colonic mucosa	UBERON:0000317	89.80	gold quality
caecum	UBERON:0001153	85.62	gold quality
colonic epithelium	UBERON:0000397	85.15	gold quality
jejunal mucosa	UBERON:0000399	84.39	gold quality
small intestine Peyer’s patch	UBERON:0003454	84.34	gold quality
small intestine	UBERON:0002108	83.55	gold quality
transverse colon	UBERON:0001157	82.56	gold quality
rectum	UBERON:0001052	78.58	gold quality
right lobe of liver	UBERON:0001114	78.32	gold quality
intestine	UBERON:0000160	75.94	gold quality
liver	UBERON:0002107	74.87	gold quality
large intestine	UBERON:0000059	73.50	gold quality
colon	UBERON:0001155	72.78	gold quality
epithelial cell of pancreas	CL:0000083	67.24	silver quality
jejunum	UBERON:0002115	64.68	gold quality
sigmoid colon	UBERON:0001159	58.99	gold quality
bone marrow cell	CL:0002092	58.54	silver quality
gall bladder	UBERON:0002110	56.97	gold quality
decidua	UBERON:0002450	56.55	gold quality
hair follicle	UBERON:0002073	53.04	gold quality
endometrium epithelium	UBERON:0004811	52.62	gold quality
cerebellar vermis	UBERON:0004720	51.12	gold quality
Brodmann (1909) area 10	UBERON:0013541	50.99	gold quality
lower lobe of lung	UBERON:0008949	50.75	silver quality
muscle layer of sigmoid colon	UBERON:0035805	50.72	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 2.

Experiment	Marker?	Max mean expression
E-MTAB-6678	yes	10.88
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): AR, CDX2, FOXA1, FOXA2, HNF1A, NCOR1, NCOR2, PBX2, PKNOX1, PRKDC

miRNA regulators (miRDB)

48 targeting UGT2B17, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-126-5P	100.00	72.71	3180
HSA-MIR-4795-3P	100.00	74.62	4024
HSA-MIR-656-3P	100.00	72.15	2788
HSA-MIR-548C-3P	99.99	74.01	7587
HSA-MIR-548AW	99.99	72.57	3559
HSA-MIR-10401-5P	99.99	65.79	948
HSA-MIR-1468-3P	99.96	72.74	3797
HSA-MIR-335-3P	99.93	73.36	4958
HSA-MIR-450B-5P	99.92	71.48	3175
HSA-MIR-3671	99.90	73.04	3897
HSA-MIR-6783-3P	99.89	67.92	2059
HSA-MIR-1343-3P	99.89	66.78	1815
HSA-MIR-182-5P	99.87	74.03	2589
HSA-MIR-5010-3P	99.83	70.60	2357
HSA-MIR-944	99.82	70.85	3042
HSA-MIR-494-3P	99.70	71.45	2795
HSA-MIR-33A-3P	99.70	70.27	3362
HSA-MIR-548AV-5P	99.60	70.84	2107
HSA-MIR-548K	99.60	70.84	2107
HSA-MIR-2053	99.57	69.15	1635
HSA-MIR-5004-3P	99.54	68.27	1371
HSA-MIR-409-3P	99.50	66.33	1192
HSA-MIR-8054	99.48	70.81	2084
HSA-MIR-569	99.42	66.32	1009
HSA-MIR-513A-3P	99.39	70.63	3620
HSA-MIR-513C-3P	99.39	70.63	3620
HSA-MIR-4786-3P	99.36	68.35	1390
HSA-MIR-6128	99.33	67.83	1581
HSA-MIR-329-5P	99.27	68.11	1597
HSA-MIR-3606-3P	99.11	69.84	3254

Literature-anchored findings (GeneRIF, showing 40)

• In human prostate, UGT2B15 and UGT2B17 genes have complementary roles and are expressed in cells where their specific substrates are synthesized. (PMID:15666817)
• UGT2B17 deletion polymorphism is associated with a reduced rate of NNAL detoxification in vivo and may increase individual susceptibility to tobacco-related cancers. (PMID:16220109)
• The UGT2B17 polymorphism is strongly associated with the bimodal distribution of testosterone excretion and also with the large difference in testosterone excretion between Koreans and Swedes. (PMID:16332934)
• Deletion polymorphism of UDP-glucuronosyltransferase 2B17 is associated with prostate cancer (PMID:16896035)
• The UGT2B17 deletion polymorphism is associated with prostate cancer risk. (PMID:17387331)
• association of the UGT2B17 deletion with increased lung adenocarcinoma in women is consistent with its association with decreased 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol glucuronidation rates in women (PMID:17416778)
• results suggest that the HSD3B1 N367T and UGT2B17 null polymorphisms may modify the risk of prostate cancer, particularly among men with a family history of the disease (PMID:17826523)
• UGT2B15 and -B17 are critical enzymes for the local inactivation of androgens and that glucuronidation is a major determinant of androgen action in prostate cells (PMID:17848572)
• These findings show that the UGT2B17 deletion polymorphism is not associated with prostate cancer risk in Caucasians. (PMID:17935910)
• Androsterone reduces the glucuronidation of androgens catalysed by UGT2B15 and UGT2B17 in a prostate tumor cell line. (PMID:17988216)
• The UGT2B17 deletion polymorphism does not play a major role in prostate cancer susceptibility as previously indicated. (PMID:18247404)
• Vitamin D receptor activator calcitriol as a negative regulator of the UGT2B15- and UGT2B17-dependent inactivation of androgens in prostate cancer LNCaP cells. (PMID:18281521)
• UGT2B17 ia a primary androgen-regulated genes and androgen receptor is required for basal expression and androgen-regulated expression. (PMID:18302198)
• Diversity was unusually high, with evidence of balancing selection in Europe. In contrast, diversity was low in East Asia where a single haplotype predominated, suggesting positive selection for the deletion in this part of the world (PMID:18760392)
• Genome-wide copy-number variation identified a susceptibility gene, UGT2B17, for osteoporosis. (PMID:18992858)
• In pubertal boys, a common homozygous deletion in the UGT2B17 gene strongly affected urinary excretion pattern of androgen metabolites but did not influence circulating androgen levels. (PMID:19088161)
• Large testosterone excretion is associated with a deletion polymorphism of the UGT2B17 gene. This polymorphism decreases T/E ratio level. (PMID:19224506)
• Copy-number variations (CNVs) of the human sex steroid metabolizing genes UGT2B17 (PMID:19572376)
• the association of deletion polymorphism in the UGT2B17 gene with the occurrence of renal disorders on chronic exposure to anabolic androgenic steroids (PMID:20429943)
• Overexpression of UGT2B17 is associated with endometrial cancer. (PMID:20554747)
• UGT2B17 expression in prostate cancer is regulated by a novel polymorphism in forkhead boxA1 binding site. (PMID:20628005)
• regulation of the UGT2B15 and UGT2B17 genes by FOXA1 may have an important role in the maintenance of androgen homeostasis within prostate cancer cells. (PMID:20736324)
• data suggest that men have a higher amount of UGT2B17 glucuronidation activity then women (PMID:20810538)
• Data suggest that UGTs 2B10 and 2B17 play important roles in the glucuronidation of nicotine and suggest that the UGT2B10 codon 67 SNP and the UGT2B17 gene deletion reduce overall glucuronidation rates of nicotine and its major metabolites in smokers. (PMID:20876810)
• we found no evidence of an effect of UGT2B17 CNV on osteoporosis risk in elderly Caucasian women. (PMID:20878390)
• Data show that steroidogenic enzymes (AKR1C3, HSD17B2, UGT2B15 and UGT2B17) and stem/progenitor cell markers CK5 and ABCG2 were upregulated in castration resistant prostate cancer. (PMID:21365123)
• UGT2B17 gene deletion associated with an increase in bone mineral density similar to the effect of hormone replacement in postmenopausal women (PMID:21614655)
• Data show that 698 CNPs loci overlap with known disease-associated or pharmacogenetic-related genes such as CFHR3, CFHR1, GSTTI and UGT2B17. (PMID:21677662)
• The UGT2B17 Del polymorphism may significantly contribute to prostate cancer susceptibility in men. (Meta-analysis) (PMID:21919858)
• The study revealed that UGT2B15 and UGT2B17 are differentially regulated during prostate cancer progression. (PMID:22170718)
• UGT2B17 and UGT2B10 play key roles in the glucuronidation of 3HC in the human liver and that functional polymorphisms in UGT2B17 and UGT2B10 are associated with significantly reduced glucuronidation activities against 3HC. (PMID:22228205)
• Genetic variations in the UGT2B17 gene dramatically affect the pharmacokinetics of MK-7246 in healthy subjects. (PMID:22669291)
• We observed a significant association between UGT2B17 expressing recipients and UGT2B17 deficient donors with the severity of Acute graft versus host disease. (PMID:22726315)
• The prevalence of the UGT2B17 deletion genotype is extremely high in Japanese subjects. (PMID:22887913)
• Data from an in vitro supersome/microsome-based assay suggest that the key steroid-metabolizing enzyme UGT2B17 is inhibited by phenolic dietary substances in red wine and therefore may reduce the rate of testosterone glucuronidation in vivo. (PMID:22958586)
• The present study was aimed to investigate the possible association between 19-base pair (bp) deletion polymorphism of the DHFR gene (rs70991108), null genotype of UGT2B17 as well as the expression level of NGX6 with the risk of breast cancer. (PMID:23053953)
• observed an exclusive involvement of the 2B17 isoform within the UGT protein family in poor-risk chronic lymphocytic leukemia (PMID:23169782)
• Report UGT2B17 expression in fetal/adult tissues. (PMID:23223495)
• The androgen receptor assay may serve as a complement to the urinary testosterone/epitestosterone (T/E) doping test, because this is profoundly influenced by the UGT2B17 deletion polymorphism. (PMID:23294483)
• Structural variants unique to the malignant cell line inactivated: UGT2B17, a gene that inactivates dihydrotestosterone, a known activator of prostate cancer progression. (PMID:23792589)

Cross-species orthologs

107 orthologs

Organism	Symbol	Gene ID
danio_rerio	ugt5d1	ENSDARG00000002394
danio_rerio	ugt5c2	ENSDARG00000006372
danio_rerio	ugt5a1	ENSDARG00000016479
danio_rerio	ugt5g1	ENSDARG00000032862
danio_rerio	ugt5g2	ENSDARG00000043901
danio_rerio	ugt5f1	ENSDARG00000054835
danio_rerio	ugt5e1	ENSDARG00000058048
danio_rerio	ugt5c3	ENSDARG00000061439
danio_rerio	ugt5c1	ENSDARG00000061444
danio_rerio	si:ch73-334d15.1	ENSDARG00000061672
danio_rerio	ugt2a7	ENSDARG00000091624
danio_rerio	ugt5b4	ENSDARG00000091916
danio_rerio	ugt2b1	ENSDARG00000093043
danio_rerio	ugt5a2	ENSDARG00000093640
danio_rerio	ugt5b3	ENSDARG00000099276
danio_rerio	ugt5b2	ENSDARG00000101495
danio_rerio	ugt5b5	ENSDARG00000104203
danio_rerio	ugt5b1	ENSDARG00000104995
danio_rerio	ugt2b3	ENSDARG00000109611
danio_rerio		ENSDARG00000110614
danio_rerio		ENSDARG00000113218
danio_rerio	ugt2b5	ENSDARG00000116986
drosophila_melanogaster	Ugt36A1	FBGN0015663
drosophila_melanogaster	Ugt35B1	FBGN0026314
drosophila_melanogaster	Ugt35A1	FBGN0026315
drosophila_melanogaster	Ugt37C1	FBGN0026754
drosophila_melanogaster	Ugt37B1	FBGN0026755
drosophila_melanogaster	Ugt37A1	FBGN0026756
drosophila_melanogaster	Ugt36E1	FBGN0027070
drosophila_melanogaster	Ugt49B1	FBGN0027073
drosophila_melanogaster	Ugt36F1	FBGN0027074
drosophila_melanogaster	Ugt307A1	FBGN0031887
drosophila_melanogaster	Ugt36D1	FBGN0032713
drosophila_melanogaster	Ugt49C1	FBGN0034605
drosophila_melanogaster	Ugt316A1	FBGN0036842
drosophila_melanogaster	Ugt37A2	FBGN0038082
drosophila_melanogaster	Ugt37A3	FBGN0038083
drosophila_melanogaster	Ugt49B2	FBGN0038886
drosophila_melanogaster	Ugt303B3	FBGN0039085
drosophila_melanogaster	Ugt303B1	FBGN0039086
drosophila_melanogaster	Ugt303B2	FBGN0039087
drosophila_melanogaster	Ugt304A1	FBGN0040250
drosophila_melanogaster	Ugt302K1	FBGN0040251
drosophila_melanogaster	Ugt303A1	FBGN0040252
drosophila_melanogaster	Ugt35E1	FBGN0040253
drosophila_melanogaster	Ugt35E2	FBGN0040255
drosophila_melanogaster	Ugt302E1	FBGN0040257
drosophila_melanogaster	Ugt302C1	FBGN0040259
drosophila_melanogaster	Ugt37D1	FBGN0040260
drosophila_melanogaster	Ugt37E1	FBGN0040261
drosophila_melanogaster	Ugt37C2	FBGN0040262
drosophila_melanogaster	Ugt305A1	FBGN0042179
drosophila_melanogaster	Ugt35D1	FBGN0051002
caenorhabditis_elegans		WBGENE00007072
caenorhabditis_elegans		WBGENE00007073
caenorhabditis_elegans		WBGENE00007402
caenorhabditis_elegans		WBGENE00007422
caenorhabditis_elegans		WBGENE00007455
caenorhabditis_elegans		WBGENE00007885
caenorhabditis_elegans		WBGENE00007946
caenorhabditis_elegans		WBGENE00008097
caenorhabditis_elegans		WBGENE00008486
caenorhabditis_elegans		WBGENE00009255
caenorhabditis_elegans		WBGENE00010904
caenorhabditis_elegans		WBGENE00011006
caenorhabditis_elegans		WBGENE00011340
caenorhabditis_elegans		WBGENE00011452
caenorhabditis_elegans		WBGENE00011453
caenorhabditis_elegans		WBGENE00012788
caenorhabditis_elegans		WBGENE00013900
caenorhabditis_elegans		WBGENE00013905
caenorhabditis_elegans		WBGENE00013906
caenorhabditis_elegans		WBGENE00015141
caenorhabditis_elegans		WBGENE00015369
caenorhabditis_elegans		WBGENE00015371
caenorhabditis_elegans		WBGENE00015449
caenorhabditis_elegans		WBGENE00015577
caenorhabditis_elegans	ugt-28	WBGENE00015693
caenorhabditis_elegans	ugt-27	WBGENE00015694
caenorhabditis_elegans	ugt-26	WBGENE00015695
caenorhabditis_elegans		WBGENE00015739
caenorhabditis_elegans		WBGENE00015965
caenorhabditis_elegans		WBGENE00016013
caenorhabditis_elegans		WBGENE00017315
caenorhabditis_elegans		WBGENE00017329
caenorhabditis_elegans		WBGENE00017331
caenorhabditis_elegans		WBGENE00017332
caenorhabditis_elegans		WBGENE00017333
caenorhabditis_elegans		WBGENE00017334
caenorhabditis_elegans		WBGENE00017336
caenorhabditis_elegans		WBGENE00017959
caenorhabditis_elegans		WBGENE00018206
caenorhabditis_elegans		WBGENE00018543
caenorhabditis_elegans		WBGENE00018931
caenorhabditis_elegans		WBGENE00019232
caenorhabditis_elegans		WBGENE00019233
caenorhabditis_elegans		WBGENE00019234
caenorhabditis_elegans		WBGENE00019235
caenorhabditis_elegans		WBGENE00019515
caenorhabditis_elegans		WBGENE00019516
caenorhabditis_elegans		WBGENE00020587
caenorhabditis_elegans		WBGENE00020592
caenorhabditis_elegans		WBGENE00020593
caenorhabditis_elegans		WBGENE00020594
caenorhabditis_elegans		WBGENE00021709
caenorhabditis_elegans		WBGENE00044282
caenorhabditis_elegans		WBGENE00044286

Paralogs (21): UGT2B10 (ENSG00000109181), UGT2A3 (ENSG00000135220), UGT2B28 (ENSG00000135226), UGT3A1 (ENSG00000145626), UGT2B4 (ENSG00000156096), UGT1A6 (ENSG00000167165), UGT3A2 (ENSG00000168671), UGT2B7 (ENSG00000171234), UGT2A1 (ENSG00000173610), UGT8 (ENSG00000174607), UGT2B15 (ENSG00000196620), UGT2B11 (ENSG00000213759), UGT1A9 (ENSG00000241119), UGT1A1 (ENSG00000241635), UGT1A8 (ENSG00000242366), UGT1A10 (ENSG00000242515), UGT1A7 (ENSG00000244122), UGT1A4 (ENSG00000244474), UGT2A2 (ENSG00000271271), UGT1A3 (ENSG00000288702), UGT1A5 (ENSG00000288705)

Protein

Protein identifiers

UDP-glucuronosyltransferase 2B17 — O75795 (reviewed: O75795)

Alternative names: C19-steroid-specific UDP-glucuronosyltransferase

All UniProt accessions (2): A0A804HJ67, O75795

UniProt curated annotations — full annotation on UniProt →

Function. UDP-glucuronosyltransferase (UGT) that catalyzes phase II biotransformation reactions in which lipophilic substrates are conjugated with glucuronic acid to increase the metabolite’s water solubility, thereby facilitating excretion into either the urine or bile. Catalyzes the glucuronidation of endogenous steroid hormones such as androgens (epitestosterone, androsterone) and estrogens (estradiol, epiestradiol).

Subcellular location. Endoplasmic reticulum membrane.

Tissue specificity. Expressed in various tissues including the liver, kidney, testis, uterus, placenta, mammary gland, adrenal gland, skin and prostate.

Polymorphism. Copy-number variation of UGT2B17 defines the bone mineral density quantitative trait locus 12 (BMND12) [MIM:612560]. Variance in bone mineral density is a susceptibility factor for osteoporotic fractures.

Similarity. Belongs to the UDP-glycosyltransferase family.

RefSeq proteins (1): NP_001068* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR002213	UDP_glucos_trans	Family
IPR035595	UDP_glycos_trans_CS	Conserved_site
IPR050271	UDP-glycosyltransferase	Family

Pfam: PF00201

Enzyme classification (BRENDA):

• EC 2.4.1.17 — glucuronosyltransferase (BRENDA: 32 organisms, 1285 substrates, 660 inhibitors, 855 Km, 6 kcat entries)

Substrate kinetics (BRENDA)

189 substrates with measured Km, best-characterized 15. Km ranges are aggregated across organisms/conditions.

Substrate	Km (mM)	Measurements
4-METHYLUMBELLIFERONE	0.0001–4.204	44
MORPHINE	0.0355–37.4	31
4-NITROPHENOL	0.0102–2	24
PROPOFOL	0.0072–0.9	19
ZIDOVUDINE	0.508–1.54	19
1-NAPHTHOL	0.0025–27	18
IMIPRAMINE	0.0072–1.442	13
TRANS-4-HYDROXYTAMOXIFEN	0.0037–0.319	13
SCOPOLETIN	0.061–7.64	11
SEROTONIN	3.7–55.9	11
2-HYDROXYESTRONE	0.0102–6	10
CIS-4-HYDROXYTAMOXIFEN	0.0074–0.193	10
DOPAMINE	1.89–3.11	10
1-HYDROXYBENZO(A)PYRENE	0.0113–2.869	9
1-HYDROXYPYRENE	0.0032–2.326	9

Catalyzed reactions (Rhea), 6 shown:

• glucuronate acceptor + UDP-alpha-D-glucuronate = acceptor beta-D-glucuronoside + UDP + H(+) (RHEA:21032)
• testosterone + UDP-alpha-D-glucuronate = testosterone 17-O-(beta-D-glucuronate) + UDP + H(+) (RHEA:52456)
• 17beta-estradiol + UDP-alpha-D-glucuronate = 17beta-estradiol 17-O-(beta-D-glucuronate) + UDP + H(+) (RHEA:52464)
• 17alpha-estradiol + UDP-alpha-D-glucuronate = 17alpha-estradiol 3-O-(beta-D-glucuronate) + UDP + H(+) (RHEA:52868)
• 17alpha-estradiol + UDP-alpha-D-glucuronate = 17alpha-estradiol 17-O-(beta-D-glucuronate) + UDP + H(+) (RHEA:52872)
• 17beta-hydroxy-5alpha-androstan-3-one + UDP-alpha-D-glucuronate = 5alpha-dihydrotestosterone 17-O-(beta-D-glucuronate) + UDP + H(+) (RHEA:53000)

UniProt features (23 total): helix 9, strand 7, glycosylation site 3, signal peptide 1, chain 1, transmembrane region 1, modified residue 1

Structure

Experimental structures (PDB)

1 structures.

PDB	Method	Resolution (Å)
7YAN	X-RAY DIFFRACTION	2.5

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-O75795-F1	93.51	0.86

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (1): 136

Glycosylation sites (3): 65, 316, 483

Function

Pathways and Gene Ontology

Reactome pathways

3 pathways

ID	Pathway
R-HSA-156588	Glucuronidation
R-HSA-9749641	Aspirin ADME
R-HSA-9757110	Prednisone ADME

MSigDB gene sets: 92 (showing top): REACTOME_BIOLOGICAL_OXIDATIONS, GOBP_REGULATION_OF_HORMONE_LEVELS, chr4q13, GOBP_LIPID_METABOLIC_PROCESS, KEGG_STARCH_AND_SUCROSE_METABOLISM, SPIELMAN_LYMPHOBLAST_EUROPEAN_VS_ASIAN_UP, SABATES_COLORECTAL_ADENOMA_DN, KEGG_STEROID_HORMONE_BIOSYNTHESIS, VECCHI_GASTRIC_CANCER_EARLY_DN, GOBP_ESTROGEN_METABOLIC_PROCESS, GOBP_STEROID_METABOLIC_PROCESS, KEGG_METABOLISM_OF_XENOBIOTICS_BY_CYTOCHROME_P450, GOCC_NUCLEAR_OUTER_MEMBRANE_ENDOPLASMIC_RETICULUM_MEMBRANE_NETWORK, KEGG_DRUG_METABOLISM_OTHER_ENZYMES, REACTOME_GLUCURONIDATION

GO Biological Process (4): xenobiotic metabolic process (GO:0006805), steroid metabolic process (GO:0008202), estrogen metabolic process (GO:0008210), lipid metabolic process (GO:0006629)

GO Molecular Function (4): glucuronosyltransferase activity (GO:0015020), UDP-glycosyltransferase activity (GO:0008194), transferase activity (GO:0016740), glycosyltransferase activity (GO:0016757)

GO Cellular Component (3): endoplasmic reticulum membrane (GO:0005789), membrane (GO:0016020), endoplasmic reticulum (GO:0005783)

Reactome top-level categories

Rollup of top-2 pathways:

Category	Pathways
Drug ADME	2
Phase II - Conjugation of compounds	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
metabolic process	1
cellular response to xenobiotic stimulus	1
lipid metabolic process	1
steroid metabolic process	1
hormone metabolic process	1
primary metabolic process	1
UDP-glycosyltransferase activity	1
hexosyltransferase activity	1
glycosyltransferase activity	1
catalytic activity	1
transferase activity	1
organelle membrane	1
nuclear outer membrane-endoplasmic reticulum membrane network	1
endoplasmic reticulum subcompartment	1
cellular anatomical structure	1
cytoplasm	1
endomembrane system	1
intracellular membrane-bounded organelle	1

Protein interactions and networks

STRING

854 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
UGT2B17	SLC35A2	P78381	932
UGT2B17	GPRIN2	O60269	831
UGT2B17	NBPF1	Q3BBV0	830
UGT2B17	B3GAT2	Q9NPZ5	827
UGT2B17	NPEPPS	P55786	827
UGT2B17	HYDIN	Q4G0P3	827
UGT2B17	SRGAP2	O75044	823
UGT2B17	DRD5	P21918	810
UGT2B17	SRGAP3	O43295	810
UGT2B17	GTF2I	P78347	763
UGT2B17	PPIG	Q13427	728
UGT2B17	CYP3A4	P05184	726
UGT2B17	CYP2C9	P11712	632
UGT2B17	CYP1A2	P05177	629
UGT2B17	CYP2C19	P33259	629

IntAct

0 interactions, top by confidence:

BioGRID (2): UGT2B17 (Affinity Capture-MS), UGT2B17 (Proximity Label-MS)

ESM2 similar proteins: A5D6U8, A6H730, J3SDX8, O16956, O35409, O61866, O75795, P04068, P04634, P07098, P07099, P07687, P08430, P0DTE5, P11515, P19224, P21529, P36510, P37891, P38571, P49614, P70627, P70691, P79381, P80035, Q28611, Q29458, Q38924, Q3U4B4, Q3YBN2, Q41005, Q4R4S5, Q5VXI9, Q5VXJ0, Q5VYY2, Q5W064, Q64194, Q64435, Q64550, Q67ZU1

Diamond homologs: A0A096SRM5, A0A0B6VIJ5, A0A0D1CFF0, A0A0M4KE44, A0A193AU77, A0A1L7U2E9, A0A224AKZ9, A0A224AM54, A0A291PQF1, A0A291PQG3, A0A291PQH4, A0A2Z5CV93, A5U6W6, B4G072, C3W7B0, G2WW48, K7NBW3, O02663, O19103, O23401, O31853, O60656, O75310, O75795, O77649, O82385, O97951, P06133, P08430, P08541, P08542, P09875, P0DTE4, P0DTE5, P16662, P17717, P19224, P19488, P20720, P22309

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

96 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	57
Likely benign	14
Benign	20

Top pathogenic / likely-pathogenic (0)

SpliceAI

621 predictions. Top by Δscore:

Variant	Effect	Δscore
4:68537900:TATAG:T	acceptor_gain	1.0000
4:68537901:ATAG:A	acceptor_gain	1.0000
4:68537902:TAG:T	acceptor_gain	1.0000
4:68537903:AG:A	acceptor_gain	1.0000
4:68537903:AGC:A	acceptor_loss	1.0000
4:68537904:GC:G	acceptor_loss	1.0000
4:68537905:C:CC	acceptor_gain	1.0000
4:68537905:CTG:C	acceptor_loss	1.0000
4:68537912:A:C	acceptor_gain	1.0000
4:68550675:A:AC	donor_gain	1.0000
4:68550676:C:CC	donor_gain	1.0000
4:68550724:TG:T	donor_gain	1.0000
4:68537903:AGCTG:A	acceptor_gain	0.9900
4:68537905:CTGAA:C	acceptor_loss	0.9900
4:68537912:A:AC	acceptor_gain	0.9900
4:68537916:A:C	acceptor_gain	0.9900
4:68537918:A:C	acceptor_gain	0.9900
4:68550676:CATA:C	donor_gain	0.9900
4:68550676:CATAG:C	donor_gain	0.9900
4:68550695:G:T	donor_gain	0.9900
4:68550696:A:AC	donor_gain	0.9900
4:68550697:C:CC	donor_gain	0.9900
4:68565567:TTCAC:T	donor_loss	0.9900
4:68565568:TCA:T	donor_loss	0.9900
4:68565569:CA:C	donor_loss	0.9900
4:68565570:A:AT	donor_loss	0.9900
4:68565571:CCTT:C	donor_loss	0.9900
4:68565571:CCTTA:C	donor_loss	0.9900
4:68565717:CTTC:C	acceptor_gain	0.9900
4:68565718:TTC:T	acceptor_gain	0.9900

AlphaMissense

3531 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
4:68551905:A:G	W338R	0.993
4:68551905:A:T	W338R	0.993
4:68550840:C:G	A384P	0.992
4:68567969:A:C	S172R	0.991
4:68567969:A:T	S172R	0.991
4:68567971:T:G	S172R	0.991
4:68550874:A:C	F372L	0.989
4:68550874:A:T	F372L	0.989
4:68550876:A:G	F372L	0.989
4:68565676:A:G	W257R	0.989
4:68565676:A:T	W257R	0.989
4:68537817:A:C	F467L	0.986
4:68537817:A:T	F467L	0.986
4:68537819:A:G	F467L	0.986
4:68550872:A:T	I373K	0.986
4:68551829:A:G	L363P	0.986
4:68551837:C:A	Q360H	0.984
4:68551837:C:G	Q360H	0.984
4:68568348:A:G	L46P	0.984
4:68537809:C:G	R470P	0.983
4:68550842:T:A	E383V	0.983
4:68551848:A:G	W357R	0.983
4:68551848:A:T	W357R	0.983
4:68550875:A:G	F372S	0.982
4:68551846:C:A	W357C	0.982
4:68551846:C:G	W357C	0.982
4:68560625:A:T	V306E	0.982
4:68551910:A:T	V336D	0.981
4:68568379:A:G	W36R	0.981
4:68568379:A:T	W36R	0.981

dbSNP variants (sampled 300 via entrez): RS10000724 (4:68547156 A>C,G,T), RS1000165226 (4:68570267 T>C), RS1000224662 (4:68571383 T>C), RS1000378999 (4:68543149 G>A), RS10004842 (4:68545413 G>A), RS10005524 (4:68540146 G>A), RS1000556570 (4:68577275 C>T), RS1000710023 (4:68551372 G>A,T), RS1000759371 (4:68552727 CAAAT>C), RS1000834502 (4:68544757 A>G,T), RS1001380816 (4:68576042 C>A), RS10015614 (4:68556844 T>A,C), RS10022369 (4:68561802 G>A,C), RS1002378148 (4:68558975 G>A), RS1002431883 (4:68560256 A>G)

Disease associations

OMIM: gene MIM:601903 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

9 associations (top):

Study	Trait	p-value
GCST010173_167	Triglyceride levels	4.000000e-08
GCST010244_276	Triglyceride levels	4.000000e-16
GCST012020_278	Serum metabolite levels	1.000000e-28
GCST012020_279	Serum metabolite levels	2.000000e-13
GCST012020_280	Serum metabolite levels	1.000000e-41
GCST012020_281	Serum metabolite levels	8.000000e-31
GCST012020_282	Serum metabolite levels	2.000000e-13
GCST012020_283	Serum metabolite levels	2.000000e-12
GCST012020_284	Serum metabolite levels	1.000000e-10

EFO canonical traits (1, from GWAS)

EFO ID	Trait name
EFO:0004530	triglyceride measurement

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (2): CHEMBL4523985 (PROTEIN FAMILY), CHEMBL4978 (SINGLE PROTEIN)

PharmGKB: 1 entry (VIP=true, CPIC=false)

PharmGKB variants

1 variants.

Variant	Genes	Level	Score	#Clin annots	Drugs
rs6817882	UGT2B17		0.00	0

Binding affinities (BindingDB)

1 measured of 1 human assays (1 total across all organisms); most potent 1 below. Values come from heterogeneous assays and are not directly comparable.

Ligand	Measure	Value
(1R)-phenyl-[(1R,2S,7S,8S,9S)-3,3,7-trimethyltricyclo[5.4.0.02,9]undec-8-yl]methanol	KI	21800 nM

CTD chemical–gene interactions

50 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Hymecromone	increases glucuronidation, increases chemical synthesis, increases metabolic processing, increases activity, decreases reaction	3
Testosterone	decreases expression, increases expression, increases metabolic processing, affects cotreatment	3
4-(methylnitrosamino)-1-(3-pyridyl)-1-butan-1-ol	increases glucuronidation, decreases glucuronidation	2
bisphenol AF	decreases activity, increases glucuronidation	2
Diclofenac	increases glucuronidation	2
Tetrachlorodibenzodioxin	affects cotreatment, decreases expression	2
Aflatoxin B1	decreases methylation, increases expression	2
tucatinib	decreases activity	1
daidzein	increases expression	1
methyleugenol	decreases expression	1
amentoflavone	decreases activity	1
4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone	increases glucuronidation	1
sodium arsenite	increases expression	1
4-methylumbelliferyl glucuronide	increases chemical synthesis, increases glucuronidation	1
caffeic acid	decreases activity	1
bicalutamide	decreases expression	1
licochalcone A	decreases reaction, increases activity	1
cylindrospermopsin	decreases expression	1
4-((methylnitrosoamino)-1-(3-pyridyl)but-1-yl)beta-omega-glucosiduronic acid	increases chemical synthesis	1
p-coumaric acid	decreases activity	1
lorcaserin	increases carbamoylation, increases glucuronidation	1
pectolinarigenin	increases glucuronidation	1
EPZ004777	decreases reaction, increases expression, affects binding	1
Vorinostat	affects binding, decreases activity, decreases glucuronidation, decreases reaction, increases glucuronidation	1
Androsterone	increases metabolic processing	1
Benzo(a)pyrene	decreases expression	1
Calcitriol	decreases expression, affects cotreatment	1
Chlorogenic Acid	decreases activity	1
Endosulfan	affects cotreatment, decreases expression	1
Estradiol	affects cotreatment, decreases expression, increases expression	1

ChEMBL screening assays

76 unique, capped per target: 71 admet, 3 binding, 2 functional

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL4339708	ADMET	Drug metabolism in human hepatocytes assessed as UGT-mediated glucuronidation by measuring O-glucuronide formation at 10 uM measured after 4 hrs by LC-MS analysis	Discovery of Imidazo[1,2-a]pyrazines and Pyrazolo[1,5-c]pyrimidines as TARP γ-8 Selective AMPAR Negative Modulators. — ACS Med Chem Lett
CHEMBL867716	Binding	Inhibition of UGT2B17	Stereochemical sensitivity of the human UDP-glucuronosyltransferases 2B7 and 2B17. — J Med Chem
CHEMBL869550	Functional	Competitive inhibition of UGT2B17-catalyzed scopoletin glucuronidation	Stereochemical sensitivity of the human UDP-glucuronosyltransferases 2B7 and 2B17. — J Med Chem

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.